SAN FRANCISCO, Aug. 3, 2026 /PRNewswire/ -- AusperBio Therapeutics Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a near-commercial Biopharmaceutical company focused on developing targeted oligonucleotide therapeutics for the treatment of chronic hepatitis B (CHB) and other...
Hence then, the article about ausperbio announces first patient dosed in clinical study of investigational hbv candidate ahb 171 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( AusperBio Announces First Patient Dosed in Clinical Study of Investigational HBV Candidate AHB-171 )
Also on site :
- Walmart’s 'Sleek' 4-Tier Bookshelf With a Drawer Is a Clever Way to Squeeze More Storage Into Small Spaces
- WWE SummerSlam 2026 Highlights Night 2: Roman Reigns conquers Seth Rollins & pays homage to Dean Ambrose (Jon Moxley); Kevin Owens returns; Chad Gable wins & more
- MarketInk: After four decades with Padres and Chargers, Bill Johnston says authenticity & trust are key in any career